Protagonist Therapeutics granted inducement awards to three recently hired employees on June 30, 2026. The awards consist of options to purchase 8,650 shares of common stock and restricted stock units for 2,275 shares. The options have an exercise price of $122.58, equal to the closing price on June 30, 2026. The options vest over four years with 25% after one year and the remainder monthly over three years, while the RSUs vest annually over four years. The awards were approved by the compensation committee as a material inducement under Nasdaq Marketplace Rule 5635(c)(4).
Protagonist Therapeutics IncInducement awards are routine hiring incentives, not a material change in company prospects.